Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
ER 172594-06 hydrobromide
CHF 0.00
In stock
SYN-3002-M0011 mgCHF 277.00
SYN-3002-M0055 mgCHF 653.00
SYN-3002-M01010 mgCHF 1'015.00
SYN-3002-M05050 mgINQ
SYN-3002-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | Atopaxar hydrobromide; ER-172594-06; E5555 |
| Product Type | Chemical |
| Properties | |
| Formula | C29H39BrFN3O5 . HBr |
| MW | 608.5 . 80.9 |
| CAS | 474550-69-1 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data | Target: N/A | Kinase Group: N/A | Substrate: N/A |
| InChi Key | UNMBLVOFOAGGCG-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
E5555 shows potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC values of 0.064 and 0.031µM, respectively.
Product References
- The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease: V.L. Serebruany, et al.; Thromb. Haemost. 102, 111 (2009)
- Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease: S. Goto, et al.; Eur. Heart J. 31, 2601 (2010)
- The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs: M. Kogushi, et al.; Eur. J. Pharmacol. 657, 131 (2011)
Related Products
